Developer docs
API playgroundTry for free, no card

Search company profiles

ProDigest

Full company profile

uuid000cwxc

Namestring
ProDigest
Legal namestring
ProDigest BV
Websiteurl
prodigest.eu
Company typeenum
Private
Founded yearint
2007
Descriptiontext

ProDigest BV is a privately held Belgian preclinical contract research organization (CRO), founded in 2007 and headquartered in Ghent, Belgium, that provides in vitro gastrointestinal simulation services to pharmaceutical, functional food/feed, and nutrition companies. The company originated from university research that developed the SHIME® (Simulator of Human Intestinal Microbial Ecosystem) platform and has built the broadest portfolio of validated ex vivo gut models in the industry, including SHIME® and its M-SHIME® mucosal variant, Colon-on-a-plate® and Kinetic Colon-on-a-plate® for high-throughput screening, Short-term colon reactors, an Upper GI tract simulator, the DIAMOD® dissolution-and-permeation platform for small molecule drugs, the MetaKey® metabolomics platform with its SIMON® multi-omics interpretation layer, and SPIME™/SCIME™/SFIME™ animal variants. These platforms are complemented by in vitro host-microbiome interaction cell assays (Caco-2/THP-1 leaky gut, wound healing, adhesion assays) and a biobank of donor microbiomes spanning healthy, diseased, infant, elderly, and animal populations.

ProDigest generates revenue primarily through fee-for-service preclinical GI studies priced per project (typical engagement durations measured in weeks, e.g., nine-week Screening SHIME® turnaround), and secondarily through one-time SHIME® instrument sales and licensing to academic institutions for non-commercial research, plus standalone MetaKey® metabolomics services for clinical and other samples. The company operates with a dedicated business development team, including a North America lead, and an internal R&D budget of over €1M per year. SHIME® has been validated across more than 200 peer-reviewed publications and was awarded a contract by the U.S. FDA's National Center for Toxicological Research as a recognized preclinical GI model, providing rare third-party regulatory validation for the platform.

Short descriptiontext

ProDigest is a Belgian preclinical CRO offering validated in vitro gastrointestinal simulation platforms (SHIME®, Colon-on-a-plate®, DIAMOD®, MetaKey®) and metabolomics services to pharmaceutical, food, feed, and nutrition companies for mechanism-of-action and formulation studies.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersGent, Belgium
HQ citystring
Gent
HQ countrystring
Belgium
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
in vitro gastrointestinal simulation, preclinical contract research, gut microbiome research services, metabolomics profiling services, drug dissolution testing
Industry3 codes
PRIMARYHLAGAAAB
Preclinical CROs (Discovery/Pharmacology/DMPK)
SECONDARYHLAGAFAC
DMPK / ADME & Bioanalysis
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Preclinical Services (Toxicology/Pharmacology/DMPK)
SECONDARYHLAGANAB
Proteomics & Mass Spectrometry Services
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Specialty Lab Services (Genomics/Proteomics/Cellomics)
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Services-Commercial Physical & Biological Research8731
Product category
Preclinical Contract Research Organization (in vitro gastrointestinal simulation and metabolomics services)
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model3 records
1Contract Research Services (CRO)
TypeProfessional Services
Description

ProDigest operates as a preclinical contract research organization offering fee-for-service GI simulation studies to food, feed, and pharma companies. Studies are tailored to client research questions, priced per project, and typically involve multi-week engagements with deliverables including microbial composition analysis, metabolomics, and host-interaction readouts.

prodigest.eu
2SHIME® Instrument Sales & Licensing
TypeLicensing Royalties
Description

ProDigest sells SHIME® technology platforms to academic institutions for non-commercial research purposes, including equipment, training, and continued scientific support. This provides a licensing/one-time revenue stream alongside recurring service revenue.

prodigest.eu
3MetaKey® Standalone Metabolomics Services
TypeProfessional Services
Description

MetaKey® metabolomics platform is offered as a self-standing service for clinical samples and other in vitro/in vivo samples (urine, blood, saliva, feces, tissues, cells), independent of GI simulation services.

prodigest.eu
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure, Supply Chain
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 11 records shown
1SHIME®
Description

Simulator of Human Intestinal Microbial Ecosystem - a full gut simulation technology for long-term microbiome interaction studies

prodigest.eu
+10 more records
Core offering1 text field

ProDigest is a preclinical Contract Research Organization (CRO) that designs, runs, and reports customized in vitro gastrointestinal (GI) tract simulation studies — using proprietary SHIME® and related platforms — for pharmaceutical, functional food/feed/nutrition, and drug delivery clients. Each study leverages physiologically representative multi-compartment reactors (stomach through colon) coupled with metabolomics (MetaKey®) and host-microbiome cell assays to generate mechanistic, IVIVC-aligned data on drug dissolution/permeation, probiotic/prebiotic/synbiotic efficacy, digestibility, and gut barrier function. The company also sells SHIME® instrument platforms and training/support to academic institutions for non-commercial research.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 6 values shown
  • SHIME® has been validated in over 150 peer-reviewed publications demonstrating in vivo-in vitro correlation
+5 more records
Product overview1 text field

ProDigest is a preclinical CRO offering a broad portfolio of in vitro gastrointestinal simulation platforms. The core technology is the SHIME® (Simulator of Human Intestinal Microbial Ecosystem) for full gut simulation. Complementary platforms include Colon-on-a-plate® and Kinetic Colon-on-a-plate® for high-throughput colonic fermentation, Short-term colon for kinetic studies, and Upper GI tract simulator for stomach and small intestine digestion. The MetaKey® metabolomics platform (including SIMON® interpretation layer and Gut Metabolite Profiling with 230 metabolites) integrates with all simulation models for metabolic analysis. Additional platforms include DIAMOD® for drug dissolution/permeation studies, Host-Microbiome Interaction Models (cell assays), and animal-specific variants (SPIME™, SCIME™, SFIMETM). The portfolio also includes M-SHIME® for mucosal simulation and Screening SHIME® for mid-throughput screening.

Product and service12 records
1SHIME® Contract Research Services
CategoryPreclinical CRO services (in vitro gastrointestinal simulation)
Description

Custom preclinical GI simulation studies using the Simulator of Human Intestinal Microbial Ecosystem (SHIME®) — the most representative in vitro technology for combined simulation of the physiological, chemical and microbiological properties of the gastrointestinal tract. Simulates all compartments from stomach through small intestine to proximal and distal colon for pharma, food, feed and nutrition clients, enabling long-term (up to 3 weeks) repeated-dosing, inter-individual variability and population-specific studies.

2M-SHIME® (Mucosal SHIME®) CRO Services
CategoryPreclinical CRO services (in vitro gastrointestinal simulation)
Description

SHIME® extended with a mucosal 'compartment' simulating the microenvironment of the gut wall, enabling study of specific roles of mucosal and luminal niches in the microbial community and assessment of localization of treatment effects and temporal onset following multiple daily doses.

3Colon-on-a-plate® CRO Services
CategoryPreclinical CRO services (high-throughput colonic simulation)
Description

High-throughput in vitro colonic fermentation service using 10 mL reactors; compares tens of test products across multiple donors and conditions in a short-term simulation up to 48 hours, providing microbial community composition, SCFA production and host-microbiome readouts.

4Kinetic Colon-on-a-plate® CRO Services
CategoryPreclinical CRO services (kinetic colonic simulation)
Description

Time-resolved, high-throughput colonic simulation service that combines small-volume scalability with multi-timepoint insight, following microbial and metabolic changes at 6, 24 and 48 hours during 48-hour fermentation in a compact 10 mL single-dose setup; captures SCFAs, lactate, gas, pH and microbial composition.

5Short-term Colon CRO Services
CategoryPreclinical CRO services (kinetic colonic simulation)
Description

Small-volume colonic reactors for scalable GI in vitro data, ideally suited to screen test products for interaction with gut microbiota, with frequent samplings from the same reactor providing kinetic insights into colonic simulation and test product effects.

6Upper GI Tract Simulator CRO Services
CategoryPreclinical CRO services (upper-GI digestion simulation)
Description

Dynamic model sequentially simulating stomach, duodenum, jejunum and ileum under fasted or fed conditions with INFOGEST 2.0 method parameters; applicable for assessing dissolution of capsules/tablets, release profiles, drug stability, probiotic survival, digestion kinetics, and bioaccessibility/bioavailability; can be coupled to colonic simulations for full-GI transit studies.

7Screening SHIME® CRO Services
CategoryPreclinical CRO services (mid-throughput full-GI simulation)
Description

Mid-throughput, fully automated computer-controlled simulation of the whole gastrointestinal tract with multiple colonic vessels tested simultaneously over an 8-day repeated dosing period; typical nine-week turnaround from experiment start to reporting.

8DIAMOD® CRO Services
CategoryPreclinical CRO services (oral drug dissolution/permeation modeling)
Description

Dynamic model recreating the physical interconnection of dissolution and permeation processes by reproducing the dynamic environment and physiology of stomach, duodenum and jejunum; designed to address poor water-solubility challenges of small molecule drug candidates, with ability to simulate achlorhydria or hypochlorhydria for patient-centric drug formulation.

9MetaKey® Metabolomics Standalone Services
CategoryPreclinical analytical services (metabolomics)
Description

Multi-approach metabolomics service combining LA-REIMS (Laser-assisted rapid evaporative ionization MS) for high-throughput metabolic fingerprinting and UHPLC-high resolution mass spectrometry for untargeted and targeted metabolic profiling, including a Gut Metabolite Profiling panel covering 230 key metabolites; sold standalone for clinical samples (urine, blood, saliva, feces, tissues, cells) or bundled with in vitro simulators.

10Host-Microbiome Interaction Cell Assay Services
CategoryPreclinical CRO services (host-microbiome cell assays)
Description

In vitro cell assays coupled to ProDigest's gut simulations including inflammation-induced leaky gut models (Caco-2 cells with THP-1 or PBMCs), wound healing assays (T84 cells) and adhesion/invasion assays; used to study gut barrier permeability, pro- and anti-inflammatory cytokines, immunomodulation, tight junction gene expression and insulin resistance.

11SHIME® Instrument Platform (Academic Sales)
CategoryIn vitro GI research equipment (academic sales)
Description

Sale of the physical SHIME® instrument platform to academic and research institutions for non-commercial research, including equipment, intensive training on operation and adaptation, and continued scientific support; distinct from the company's CRO service offering, generating equipment/licensing revenue.

12Animal GI Model CRO Services (SPIME™ / SCIME™ / SFIME™)
CategoryPreclinical CRO services (animal GI simulation)
Description

CRO services using ProDigest's SPIME™ (pig), SCIME™ (canine) and SFIME™ (feline) intestinal microbial ecosystem simulators for screening feed ingredients, bioactive compounds, formulation development and dosage; short-term setups available for other animal species.

Scale indicator8 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-03-01
Description

Sacco System — holder of one of the world's most diverse microbial culture collections — partnered with ProDigest for a collaborative study exploring how specific probiotic strains support gut barrier function and modulate immune responses. The study used ProDigest's Caco-2/THP-1 inflammation-induced leaky gut model to assess barrier integrity and immunomodulation, enabling systematic screening of multiple strains under controlled, reproducible conditions. The collaboration revealed strain-specific effects and provided actionable insights for targeted probiotic solutions.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-01-21
Description

ProDigest partnered with FutureCeuticals to conduct research demonstrating the prebiotic benefits of FutureCeuticals' Organic NatureKnit® using ProDigest's validated M-SHIME model. The study, published in Frontiers in Nutrition, showed that just 2.5 grams of NatureKnit produced a more sustained prebiotic effect at 48 hours across gut bacteria abundance, species richness, and total short-chain fatty acids compared to purified fiber alternatives. This partnership generates peer-reviewed validation for FutureCeuticals' product claims.

3U.S. FDA (National Center for Toxicological Research)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-01-01
Description

The U.S. Food and Drug Administration's National Center for Toxicological Research awarded ProDigest a contract to provide a SHIME® technology platform for full gut simulation. This milestone highlights SHIME®'s value in regulatory research and the growing role of advanced in vitro tools in preclinical decision-making within government regulatory agencies.

prodigest.eu
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-01-01
Description

Marinova used ProDigest's SHIME® model to study fucoidan polysaccharides, confirming their fermentation and the production of immune-relevant metabolites. Results showed consistent fermentation patterns and immune-relevant metabolite production, evidence that strengthened Marinova's immune health positioning and global evidence package for its marine biotechnology products.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2020-01-01
Description

The Site Drug project (subsidy contract 2S07-033), funded by Interreg 2 Seas programme 2014-2020 and the European Regional Development Fund (Start: 01/01/2020; End: 30/09/2022), aimed to develop innovative site-specific drug delivery systems for patients suffering from Crohn's disease, ulcerative colitis, ovarian cancer with peritoneal metastases, breast resection, and hearing loss. ProDigest contributed GI simulation expertise to this multi-partner collaborative drug delivery initiative.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Eurofins is a global testing services provider covering food, pharma, environmental, and clinical testing. Its CDMO and CRO services overlap with ProDigest's pharma testing and food analysis capabilities at much greater scale and broader geographic reach.

TypeEmerging player
Description

NIZO is a Dutch contract research organization specializing in food, nutrition, and microbiome research with in vitro and clinical capabilities. They directly compete for food and feed industry R&D budgets with microbiome-focused offerings similar in scope to ProDigest's food/feed segment.

TypeBroad incumbent
Description

Charles River Labs is one of the largest global preclinical CROs offering broader safety, discovery, and manufacturing services. They compete for the same pharma R&D budgets, though their portfolio extends well beyond ProDigest's GI specialization into general toxicology and manufacturing.

4TNO
TypeDirect peer
Description

TNO is a Dutch applied research organization that operates TIM-1 and TIM-2 dynamic in vitro gastrointestinal models. These models directly compete with SHIME® for GI simulation CRO work in food, pharma, and feed applications, making TNO the closest direct peer.

TypeBroad incumbent
Description

WuXi AppTec is a leading global CRO/CDMO with comprehensive preclinical and clinical capabilities. While broader than ProDigest, WuXi serves overlapping pharma and biotech customers with preclinical study budgets and could expand into specialized GI services.

TypeBroad incumbent
Description

SGS is a global inspection, verification, testing, and certification company. Its life sciences and food testing services compete for pharma and food industry R&D budgets, though at much broader scope and scale than ProDigest's specialized GI focus.

TypeDirect peer
Description

Inotiv is a US-listed preclinical CRO providing contract research services in discovery, safety assessment, and analytical services for pharma and biotech. They compete for similar pharma R&D budgets and have invested in microbiome-related preclinical capabilities.

TypeRegional player
Description

Mérieux NutriSciences is a global food testing and safety services provider with strong pharma-adjacent capabilities. Their food and nutrition testing services overlap with ProDigest's food and feed customer segments, particularly in regulatory testing and product validation.

TypeEmerging player
Description

BioIVT provides biospecimens, including gut microbiome samples, and supports pharma research with related services. While more specimen-focused, they overlap with ProDigest's biobank offerings and microbiome research customer base in pharma.

TypeBroad incumbent
Description

Thermo Fisher Scientific, through its PPD clinical research services, is a global life sciences platform offering CRO services across discovery, preclinical, and clinical stages. They compete for the same enterprise pharma R&D budgets with a much broader service catalog.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature11 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles13 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

ProDigest

Preclinical Contract Research Organization (in vitro gastrointestinal simulation and metabolomics services)prodigest.eu

ProDigest is a Belgian preclinical CRO offering validated in vitro gastrointestinal simulation platforms (SHIME®, Colon-on-a-plate®, DIAMOD®, MetaKey®) and metabolomics services to pharmaceutical, food, feed, and nutrition companies for mechanism-of-action and formulation studies.

What ProDigest does

ProDigest BV is a privately held Belgian preclinical contract research organization (CRO), founded in 2007 and headquartered in Ghent, Belgium, that provides in vitro gastrointestinal simulation services to pharmaceutical, functional food/feed, and nutrition companies. The company originated from university research that developed the SHIME® (Simulator of Human Intestinal Microbial Ecosystem) platform and has built the broadest portfolio of validated ex vivo gut models in the industry, including SHIME® and its M-SHIME® mucosal variant, Colon-on-a-plate® and Kinetic Colon-on-a-plate® for high-throughput screening, Short-term colon reactors, an Upper GI tract simulator, the DIAMOD® dissolution-and-permeation platform for small molecule drugs, the MetaKey® metabolomics platform with its SIMON® multi-omics interpretation layer, and SPIME™/SCIME™/SFIME™ animal variants. These platforms are complemented by in vitro host-microbiome interaction cell assays (Caco-2/THP-1 leaky gut, wound healing, adhesion assays) and a biobank of donor microbiomes spanning healthy, diseased, infant, elderly, and animal populations.

ProDigest generates revenue primarily through fee-for-service preclinical GI studies priced per project (typical engagement durations measured in weeks, e.g., nine-week Screening SHIME® turnaround), and secondarily through one-time SHIME® instrument sales and licensing to academic institutions for non-commercial research, plus standalone MetaKey® metabolomics services for clinical and other samples. The company operates with a dedicated business development team, including a North America lead, and an internal R&D budget of over €1M per year. SHIME® has been validated across more than 200 peer-reviewed publications and was awarded a contract by the U.S. FDA's National Center for Toxicological Research as a recognized preclinical GI model, providing rare third-party regulatory validation for the platform.

ProDigest firmographics

Firmographics
Name
ProDigest
Legal name
ProDigest BV
Website
https://prodigest.eu
Company type
Private
Founded year
2007
Operating status
Operating
Headcount range
51–100 employees
Short description
ProDigest is a Belgian preclinical CRO offering validated in vitro gastrointestinal simulation platforms (SHIME®, Colon-on-a-plate®, DIAMOD®, MetaKey®) and metabolomics services to pharmaceutical, food, feed, and nutrition companies for mechanism-of-action and formulation studies.
Ownership category
akta.pro rank

ProDigest industry classification

Industry
Product category
Preclinical Contract Research Organization (in vitro gastrointestinal simulation and metabolomics services)
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAGAAAB
Preclinical CROs (Discovery/Pharmacology/DMPK)
SECONDARYHLAGAFAC
DMPK / ADME & Bioanalysis
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Preclinical Services (Toxicology/Pharmacology/DMPK)
SECONDARYHLAGANAB
Proteomics & Mass Spectrometry Services
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Specialty Lab Services (Genomics/Proteomics/Cellomics)

Keywords

  • In vitro gastrointestinal simulation
  • Preclinical contract research
  • Gut microbiome research services
  • Metabolomics profiling services
  • Drug dissolution testing

Where ProDigest is headquartered

Location

Headquarters

HQ city
Gent
HQ country
Belgium
HQ region
Europe

Offices1 record

Markets served

ProDigest business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure, Supply Chain

Revenue model

  1. Contract Research Services (CRO): ProDigest operates as a preclinical contract research organization offering fee-for-service GI simulation studies to food, feed, and pharma companies. Studies are tailored to client research questions, priced per project, and typically involve multi-week engagements with deliverables including microbial composition analysis, metabolomics, and host-interaction readouts.
  2. SHIME® Instrument Sales & Licensing: ProDigest sells SHIME® technology platforms to academic institutions for non-commercial research purposes, including equipment, training, and continued scientific support. This provides a licensing/one-time revenue stream alongside recurring service revenue.
  3. MetaKey® Standalone Metabolomics Services: MetaKey® metabolomics platform is offered as a self-standing service for clinical samples and other in vitro/in vivo samples (urine, blood, saliva, feces, tissues, cells), independent of GI simulation services.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels6 records

ProDigest product offering

Product offering

Core offering

ProDigest is a preclinical Contract Research Organization (CRO) that designs, runs, and reports customized in vitro gastrointestinal (GI) tract simulation studies — using proprietary SHIME® and related platforms — for pharmaceutical, functional food/feed/nutrition, and drug delivery clients. Each study leverages physiologically representative multi-compartment reactors (stomach through colon) coupled with metabolomics (MetaKey®) and host-microbiome cell assays to generate mechanistic, IVIVC-aligned data on drug dissolution/permeation, probiotic/prebiotic/synbiotic efficacy, digestibility, and gut barrier function. The company also sells SHIME® instrument platforms and training/support to academic institutions for non-commercial research.

Product overview

ProDigest is a preclinical CRO offering a broad portfolio of in vitro gastrointestinal simulation platforms. The core technology is the SHIME® (Simulator of Human Intestinal Microbial Ecosystem) for full gut simulation. Complementary platforms include Colon-on-a-plate® and Kinetic Colon-on-a-plate® for high-throughput colonic fermentation, Short-term colon for kinetic studies, and Upper GI tract simulator for stomach and small intestine digestion. The MetaKey® metabolomics platform (including SIMON® interpretation layer and Gut Metabolite Profiling with 230 metabolites) integrates with all simulation models for metabolic analysis. Additional platforms include DIAMOD® for drug dissolution/permeation studies, Host-Microbiome Interaction Models (cell assays), and animal-specific variants (SPIME™, SCIME™, SFIMETM). The portfolio also includes M-SHIME® for mucosal simulation and Screening SHIME® for mid-throughput screening.

Differentiator

Problem solved

Functional benefit

Brands

  • SHIME®: Simulator of Human Intestinal Microbial Ecosystem - a full gut simulation technology for long-term microbiome interaction studies
  • Colon-on-a-plate®
  • MetaKey®
  • Screening SHIME®
  • DIAMOD®
  • M-SHIME®
  • Kinetic Colon-on-a-plate®
  • SPIME™
  • SCIME™
  • SFIMETM
  • SIMON®

Products and services

  • SHIME® Contract Research Services Custom preclinical GI simulation studies using the Simulator of Human Intestinal Microbial Ecosystem (SHIME®) — the most representative in vitro technology for combined simulation of the physiological, chemical and microbiological properties of the gastrointestinal tract. Simulates all compartments from stomach through small intestine to proximal and distal colon for pharma, food, feed and nutrition clients, enabling long-term (up to 3 weeks) repeated-dosing, inter-individual variability and population-specific studies.
  • M-SHIME® (Mucosal SHIME®) CRO Services SHIME® extended with a mucosal 'compartment' simulating the microenvironment of the gut wall, enabling study of specific roles of mucosal and luminal niches in the microbial community and assessment of localization of treatment effects and temporal onset following multiple daily doses.
  • Colon-on-a-plate® CRO Services High-throughput in vitro colonic fermentation service using 10 mL reactors; compares tens of test products across multiple donors and conditions in a short-term simulation up to 48 hours, providing microbial community composition, SCFA production and host-microbiome readouts.
  • Kinetic Colon-on-a-plate® CRO Services Time-resolved, high-throughput colonic simulation service that combines small-volume scalability with multi-timepoint insight, following microbial and metabolic changes at 6, 24 and 48 hours during 48-hour fermentation in a compact 10 mL single-dose setup; captures SCFAs, lactate, gas, pH and microbial composition.
  • Short-term Colon CRO Services Small-volume colonic reactors for scalable GI in vitro data, ideally suited to screen test products for interaction with gut microbiota, with frequent samplings from the same reactor providing kinetic insights into colonic simulation and test product effects.
  • Upper GI Tract Simulator CRO Services Dynamic model sequentially simulating stomach, duodenum, jejunum and ileum under fasted or fed conditions with INFOGEST 2.0 method parameters; applicable for assessing dissolution of capsules/tablets, release profiles, drug stability, probiotic survival, digestion kinetics, and bioaccessibility/bioavailability; can be coupled to colonic simulations for full-GI transit studies.
  • Screening SHIME® CRO Services Mid-throughput, fully automated computer-controlled simulation of the whole gastrointestinal tract with multiple colonic vessels tested simultaneously over an 8-day repeated dosing period; typical nine-week turnaround from experiment start to reporting.
  • DIAMOD® CRO Services Dynamic model recreating the physical interconnection of dissolution and permeation processes by reproducing the dynamic environment and physiology of stomach, duodenum and jejunum; designed to address poor water-solubility challenges of small molecule drug candidates, with ability to simulate achlorhydria or hypochlorhydria for patient-centric drug formulation.
  • MetaKey® Metabolomics Standalone Services Multi-approach metabolomics service combining LA-REIMS (Laser-assisted rapid evaporative ionization MS) for high-throughput metabolic fingerprinting and UHPLC-high resolution mass spectrometry for untargeted and targeted metabolic profiling, including a Gut Metabolite Profiling panel covering 230 key metabolites; sold standalone for clinical samples (urine, blood, saliva, feces, tissues, cells) or bundled with in vitro simulators.
  • Host-Microbiome Interaction Cell Assay Services In vitro cell assays coupled to ProDigest's gut simulations including inflammation-induced leaky gut models (Caco-2 cells with THP-1 or PBMCs), wound healing assays (T84 cells) and adhesion/invasion assays; used to study gut barrier permeability, pro- and anti-inflammatory cytokines, immunomodulation, tight junction gene expression and insulin resistance.
  • SHIME® Instrument Platform (Academic Sales) Sale of the physical SHIME® instrument platform to academic and research institutions for non-commercial research, including equipment, intensive training on operation and adaptation, and continued scientific support; distinct from the company's CRO service offering, generating equipment/licensing revenue.
  • Animal GI Model CRO Services (SPIME™ / SCIME™ / SFIME™) CRO services using ProDigest's SPIME™ (pig), SCIME™ (canine) and SFIME™ (feline) intestinal microbial ecosystem simulators for screening feed ingredients, bioactive compounds, formulation development and dosage; short-term setups available for other animal species.

Quantifiable outcome

  • SHIME® has been validated in over 150 peer-reviewed publications demonstrating in vivo-in vitro correlation
  • +5 more outcomes

Companies that use ProDigest

Customer profile

Named customers3 records

Segments4 records

Ideal customer profiles4 records

ProDigest technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature11 records

ProDigest partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered core and minor.

  • Sacco SystemcoreStrategic or Co-development Partner · 1 March 2026Sacco System — holder of one of the world's most diverse microbial culture collections — partnered with ProDigest for a collaborative study exploring how specific probiotic strains support gut barrier function and modulate immune responses. The study used ProDigest's Caco-2/THP-1 inflammation-induced leaky gut model to assess barrier integrity and immunomodulation, enabling systematic screening of multiple strains under controlled, reproducible conditions. The collaboration revealed strain-specific effects and provided actionable insights for targeted probiotic solutions.
  • FutureCeuticalscoreStrategic or Co-development Partner · 21 January 2026ProDigest partnered with FutureCeuticals to conduct research demonstrating the prebiotic benefits of FutureCeuticals' Organic NatureKnit® using ProDigest's validated M-SHIME model. The study, published in Frontiers in Nutrition, showed that just 2.5 grams of NatureKnit produced a more sustained prebiotic effect at 48 hours across gut bacteria abundance, species richness, and total short-chain fatty acids compared to purified fiber alternatives. This partnership generates peer-reviewed validation for FutureCeuticals' product claims.
  • U.S. FDA (National Center for Toxicological Research)coreStrategic or Co-development Partner · 1 January 2024The U.S. Food and Drug Administration's National Center for Toxicological Research awarded ProDigest a contract to provide a SHIME® technology platform for full gut simulation. This milestone highlights SHIME®'s value in regulatory research and the growing role of advanced in vitro tools in preclinical decision-making within government regulatory agencies.
  • MarinovacoreStrategic or Co-development Partner · 1 January 2021Marinova used ProDigest's SHIME® model to study fucoidan polysaccharides, confirming their fermentation and the production of immune-relevant metabolites. Results showed consistent fermentation patterns and immune-relevant metabolite production, evidence that strengthened Marinova's immune health positioning and global evidence package for its marine biotechnology products.
  • Interreg 2 Seas / European Regional Development FundminorStrategic or Co-development Partner · 1 January 2020The Site Drug project (subsidy contract 2S07-033), funded by Interreg 2 Seas programme 2014-2020 and the European Regional Development Fund (Start: 01/01/2020; End: 30/09/2022), aimed to develop innovative site-specific drug delivery systems for patients suffering from Crohn's disease, ulcerative colitis, ovarian cancer with peritoneal metastases, breast resection, and hearing loss. ProDigest contributed GI simulation expertise to this multi-partner collaborative drug delivery initiative.

Scale indicators8 records

Recent moves6 records

Expansion highlights5 records

ProDigest competitors and assessment

Company assessment

Broad incumbents

  • Eurofins Scientific: Eurofins is a global testing services provider covering food, pharma, environmental, and clinical testing. Its CDMO and CRO services overlap with ProDigest's pharma testing and food analysis capabilities at much greater scale and broader geographic reach.
  • Charles River Laboratories: Charles River Labs is one of the largest global preclinical CROs offering broader safety, discovery, and manufacturing services. They compete for the same pharma R&D budgets, though their portfolio extends well beyond ProDigest's GI specialization into general toxicology and manufacturing.
  • WuXi AppTec: WuXi AppTec is a leading global CRO/CDMO with comprehensive preclinical and clinical capabilities. While broader than ProDigest, WuXi serves overlapping pharma and biotech customers with preclinical study budgets and could expand into specialized GI services.
  • SGS: SGS is a global inspection, verification, testing, and certification company. Its life sciences and food testing services compete for pharma and food industry R&D budgets, though at much broader scope and scale than ProDigest's specialized GI focus.
  • Thermo Fisher Scientific: Thermo Fisher Scientific, through its PPD clinical research services, is a global life sciences platform offering CRO services across discovery, preclinical, and clinical stages. They compete for the same enterprise pharma R&D budgets with a much broader service catalog.

Emerging players

  • NIZO food research: NIZO is a Dutch contract research organization specializing in food, nutrition, and microbiome research with in vitro and clinical capabilities. They directly compete for food and feed industry R&D budgets with microbiome-focused offerings similar in scope to ProDigest's food/feed segment.
  • BioIVT: BioIVT provides biospecimens, including gut microbiome samples, and supports pharma research with related services. While more specimen-focused, they overlap with ProDigest's biobank offerings and microbiome research customer base in pharma.

Direct peers

  • TNO: TNO is a Dutch applied research organization that operates TIM-1 and TIM-2 dynamic in vitro gastrointestinal models. These models directly compete with SHIME® for GI simulation CRO work in food, pharma, and feed applications, making TNO the closest direct peer.
  • Inotiv: Inotiv is a US-listed preclinical CRO providing contract research services in discovery, safety assessment, and analytical services for pharma and biotech. They compete for similar pharma R&D budgets and have invested in microbiome-related preclinical capabilities.

Regional players

  • Mérieux NutriSciences: Mérieux NutriSciences is a global food testing and safety services provider with strong pharma-adjacent capabilities. Their food and nutrition testing services overlap with ProDigest's food and feed customer segments, particularly in regulatory testing and product validation.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks7 records

Key highlights7 records

Customer concentration

ProDigest social profiles

Digital presence

ProDigest compliance and trust

Trust signal

Compliance2 records

ProDigest financial estimates

Financial estimate

Revenue estimate

Valuation estimate

ProDigest leadership team

Management profile

Number of profiles

Profiles13 records

ProDigest funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

ProDigest M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about ProDigest

What does ProDigest do?

ProDigest is a preclinical Contract Research Organization (CRO) that designs, runs, and reports customized in vitro gastrointestinal (GI) tract simulation studies — using proprietary SHIME® and related platforms — for pharmaceutical, functional food/feed/nutrition, and drug delivery clients. Each study leverages physiologically representative multi-compartment reactors (stomach through colon) coupled with metabolomics (MetaKey®) and host-microbiome cell assays to generate mechanistic, IVIVC-aligned data on drug dissolution/permeation, probiotic/prebiotic/synbiotic efficacy, digestibility, and gut barrier function. The company also sells SHIME® instrument platforms and training/support to academic institutions for non-commercial research.

Is ProDigest a public or private company?

ProDigest is a private company. It is classified as venture growth investor backed and is currently operating.

When was ProDigest founded?

ProDigest was founded in 2007. It employs 51 to 100 people.

Where is ProDigest based?

ProDigest is headquartered in Gent, Belgium, in the Europe region.

How does ProDigest make money?

Three revenue lines are on record. Contract Research Services (CRO) is the primary driver. The others are SHIME® Instrument Sales & Licensing and metaKey® Standalone Metabolomics Services.

Who are ProDigest's main competitors?

Broad incumbents on record are Eurofins Scientific, Charles River Laboratories, WuXi AppTec, SGS and Thermo Fisher Scientific. Emerging players are NIZO food research and BioIVT. Direct peers are TNO and Inotiv. Mérieux NutriSciences is listed as a regional player.

Does ProDigest have an API?

No public API is recorded for ProDigest.

What industry is ProDigest in?

ProDigest's product category is Preclinical Contract Research Organization (in vitro gastrointestinal simulation and metabolomics services). Its primary akta.pro industry code is HLAGAAAB, Preclinical CROs (Discovery/Pharmacology/DMPK), with a secondary code of HLAGAFAC, DMPK / ADME & Bioanalysis. Its NAICS code is 541714 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireUn nuevo estudio revela que NatureKnit® orgánico ofrece más beneficios prebióticos que las fibras purificadasA new study published in Frontiers in Nutrition has demonstrated that Organic NatureKnit®, a patent-pending gut health ingredient developed by FutureCeuticals, exhibits significantly greater prebiotic activity in the human gut microbiome compared to commonly used purified organic fibers. Using ProDigest's validated M-SHIME model, researchers found that just 2.5 grams of Organic NatureKnit produced sustained fermentation and prebiotic effects, outperforming purified fibers in healthy gut bacteria abundance, species richness, and short-chain fatty acid production at 48 hours. FutureCeuticals highlighted the ingredient as a natural, organic, and sustainable alternative for the functional food, beverage, and dietary supplement markets.PR NewswireUne nouvelle étude révèle que le produit biologique NatureKnit® offre des avantages prébiotiques supérieurs à ceux des fibres purifiéesA new study published in Frontiers in Nutrition found that Organic NatureKnit®, a patented natural ingredient developed by FutureCeuticals, demonstrates superior prebiotic activity in the human gut microbiome compared to commonly used purified organic fibers. The research, conducted in partnership with ProDigest using their validated M-SHIME model, showed that just 2.5 grams of NatureKnit produced significantly greater prebiotic effects after 48 hours on measures of healthy gut bacteria abundance, bacterial species richness, and short-chain fatty acids. FutureCeuticals views the findings as an exciting development for the nutrition industry, positioning NatureKnit as a differentiated ingredient for gut health products.PR NewswireNeue Studie zeigt, dass Bio NatureKnit® einen größeren präbiotischen Nutzen bietet als gereinigte FasernNew research published in Frontiers in Nutrition found that Organic NatureKnit®, a natural gut health ingredient developed by FutureCeuticals, demonstrates significant and sustained prebiotic activity in the human gut microbiome. Using ProDigest's M-SHIME model, the study showed that just 2.5 grams of Organic NatureKnit produced greater prebiotic effects—including higher counts of healthy gut bacteria, greater bacterial species richness, and increased short-chain fatty acids—compared to popular purified organic fibers after 48 hours.PR NewswireNew Study Reveals Organic NatureKnit® Provides Greater Prebiotic Benefits Than Purified FibersNew research published in Frontiers in Nutrition, conducted in partnership with ProDigest, has demonstrated that FutureCeuticals' Organic NatureKnit exhibits significantly greater prebiotic activity in the human gut microbiome compared to commonly used purified organic fiber ingredients. The study used ProDigest's validated M-SHIME model to show that just 2.5 grams of NatureKnit produced a more sustained prebiotic effect at 48 hours across measures of healthy gut bacteria abundance, bacterial species richness, and total short-chain fatty acids than purified fiber alternatives. FutureCeuticals highlights this as evidence that their patent-pending blend of diverse fruit and vegetable fibers with naturally occurring fiber-bound polyphenols offers broader microbiome benefits than purified fibers.PR NewswireProDigest and CosmosID Announce a Winner for the 'Gut Microbiome Therapeutic Innovation' ChallengeThe El Aidy lab from the University of Groningen has been selected as the winner of the Gut Microbiome Therapeutic Innovation challenge organized by ProDigest and CosmosID. Their winning research proposal will investigate how anti-Parkinson's Disease medication affects gut bacterial composition and microbial activity using ProDigest's SHIME® in vitro platform combined with CosmosID's microbiome analysis technology. The study aims to advance understanding of the gut-brain axis and pharmacomicrobiomics, examining how gut microbes impact drug absorption and gastrointestinal side effects.PR NewswireProDigest and CosmosID Launch the 'Gut Microbiome Therapeutic Innovation' ChallengeProDigest and CosmosID announced the launch of the 'Gut Microbiome Therapeutic Innovation' challenge, a scientific competition where the winning abstract will receive a pre-clinical gastrointestinal study using ProDigest's SHIME® in vitro simulator combined with CosmosID's microbiome analysis platform. The challenge aims to advance understanding of microbiome-based therapeutics and their effects on gut microbiota activity and composition. Abstract submissions open February 5, 2020 and close March 31, 2020, with winners selected based on research creativity, scientific impact, and innovation.PR NewswireImmune Advisors publica estudo revisto por pares demonstrando a eficácia de um suplemento probiótico e de enzimas digestivas na proteção contra os efeitos colaterais da quimioterapia contra o câncerImmune Advisors announced the publication of a peer-reviewed study in Oncotarget demonstrating that Daily Body Restore (DBR), a commercially available supplement combining nine probiotic strains and ten digestive enzymes, can neutralize the negative effects of chemotherapy agent 5-fluorouracil and antibiotic vancomycin on gut microbiome using an in vitro bioreactor model simulating intestinal conditions. The study was conducted in collaboration with ProDigest, a Belgian company that performed the in vitro testing, with co-authors from Pacific Neuroscience Institute. Thomas Ichim of Immune Advisors stated that the data supports the viability of administering Daily Body Restore in chemotherapy patients, noting growing medical awareness of gut bacteria's role in immune system formation and drug response.PR NewswireImmune Advisors publica un estudio en el que se demuestra la eficacia de un suplemento probiótico con enzimas digestivasImmune Advisors, LLC published a study in the journal Oncotarget demonstrating that the probiotic supplement Daily Body Restore® mitigates gut microbiota dysbiosis caused by chemotherapy and antibiotics. The research, conducted using an in vitro model validated by ProDigest, showed that the supplement improved bacterial community composition and activity affected by drugs such as 5-fluorouracil and vancomycin.PR NewswireImmune Advisors publie une étude révisée par des pairs démontrant l'efficacité d'un supplément probiotique avec enzymes digestives dans la protection contre les effets secondaires de la chimiothérapieImmune Advisors, LLC announced the publication of a peer-reviewed study in Oncotarget demonstrating that Daily Body Restore® (DBR®), a commercial supplement combining nine probiotic strains and ten digestive enzymes, protects gut microbiome bacteria from damage caused by chemotherapy agent 5-fluorouracil and antibiotic vancomycin in an in vitro model. The study, conducted by ProDigest in Belgium, showed that DBR® increased the number and activity of microbial communities adversely affected by the chemotherapy drug and antibiotic. The study was co-authored by researchers from Immune Advisors, Pacific Neuroscience Institute, John Wayne Cancer Institute, and Daily Body Restore®, LLC.PR NewswireImmune Advisors publica estudio revisado por pares que demuestra la eficacia de un suplemento probiótico y de enzimas digestivas en la protección contra los efectos secundarios de la quimioterapia parImmune Advisors, LLC announced the publication of a peer-reviewed study in the journal Oncotarget demonstrating that Daily Body Restore (DBR)®, a market-available supplement combining nine probiotic strains and ten digestive enzymes, can counteract the negative effects of the chemotherapy agent 5-fluorouracil (5-FU) and the antibiotic vancomycin on the gut microbiome. The in vitro study used bioreactor models simulating intestinal tract conditions and was conducted in collaboration with ProDigest, a Belgian research company. The results suggest potential clinical applicability for cancer patients undergoing chemotherapy, a population for whom gut microbiome disruption is a known side effect that may reduce the efficacy of immunotherapy treatments.